Sorroche, B.P.; Teixeira, R.d.J.; Pereira, C.A.D.; Santana, I.V.V.; Vujanovic, L.; Vazquez, V.d.L.; Arantes, L.M.R.B.
PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil. Diagnostics 2023, 13, 1041.
https://doi.org/10.3390/diagnostics13061041
AMA Style
Sorroche BP, Teixeira RdJ, Pereira CAD, Santana IVV, Vujanovic L, Vazquez VdL, Arantes LMRB.
PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil. Diagnostics. 2023; 13(6):1041.
https://doi.org/10.3390/diagnostics13061041
Chicago/Turabian Style
Sorroche, Bruna Pereira, Renan de Jesus Teixeira, Caio Augusto Dantas Pereira, Iara Viana Vidigal Santana, Lazar Vujanovic, Vinicius de Lima Vazquez, and Lidia Maria Rebolho Batista Arantes.
2023. "PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil" Diagnostics 13, no. 6: 1041.
https://doi.org/10.3390/diagnostics13061041
APA Style
Sorroche, B. P., Teixeira, R. d. J., Pereira, C. A. D., Santana, I. V. V., Vujanovic, L., Vazquez, V. d. L., & Arantes, L. M. R. B.
(2023). PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil. Diagnostics, 13(6), 1041.
https://doi.org/10.3390/diagnostics13061041
